Author

Xinting Xia

Institutions: Shanghai Changning Maternity and Infant Health Hospital, East China Normal University

Observed institutions: Shanghai Changning Maternity and Infant Health Hospital, East China Normal University

ORCID: 0000-0003-3890-7807

Observed ORCID: 0000-0003-3890-7807

OpenAlex ID: A5003052557

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer

2023 · Juanjuan Feng, Zhongwei Hu, et al. · Oncogene · 103

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer

2022 · Juanjuan Feng, Zhengke Lian, et al. · Acta Pharmaceutica Sinica B · 65

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers

2025 · Juanjuan Feng, Xuanzheng Xiao, et al. · Cancer Cell · 42

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance

2023 · Peng He, Juanjuan Feng, et al. · Journal of Medicinal Chemistry · 31

Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-d]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRASG12D Inhibitors

2023 · Xuanzheng Xiao, Juanjuan Feng, et al. · Journal of Medicinal Chemistry · 23

Works count: 5

Citation count: 264

H-index: 5

I10-index: 5